Ascendia

  MARKET NEWS

Cereno Scientific Reports Robust Safety & Tolerability in Long‑Term CS1 Pulmonary Arterial Hypertension Study
ANI Pharmaceuticals Announces Publication of NEW DAY Clinical Trial Results in Ophthalmology
FORE Biotherapeutics Receives Breakthrough Therapy Designation for Plixorafenib
Adragos Pharma Finalizes the Acquisition of Commercial-Scale, Sterile Fill-Finish Manufacturing Site From Sanofi
Cyclerion Therapeutics & Korsana Biosciences Announce Merger Agreement
Amprion Grows Global Footprint With Australian Partnership & Expanded Research Collaborations

  EXPERT CONTENT & RESOURCES

eBook: Understanding the Foundation of LNP Formulation Success

eBook: Understanding the Foundation of LNP Formulation Success

Lipid nanoparticles (LNPs) are one of the most significant advances in drug delivery in decades. But developing successful LNP formulations demands deep knowledge of their key building blocks: Lipids.

Portrait of Dr. Lara Zibners

The Most Underutilized Route in Drug Delivery: How Vaginal Therapeutics Are Finally Getting the Platform They Deserve

Before we dig into improved delivery methods, we need to acknowledge a more basic issue: women need more therapeutics in the first place. Persistent gaps exist across conditions that uniquely or disproportionally affect women. Gynecologic infections, endometriosis, the vaginal microbiome. Menopause, contraception, oncology.

Serán Bioscience presentation title slide: 'Right from the Start: Drug Product Design for Rapid Clinical Development' by Micah Tuttle

VIDEO - Built for the Clinic: Smart Drug Product Design for Accelerated Clinical Development

In this talk, Micah Tuttle demonstrates how intentional, forward-looking drug product design from day one can dramatically accelerate clinical development—eliminating the need for costly, time-consuming reformulations and bridging studies.

Dr. Steven Quay, Founder and CEO of Atossa Therapeutics

Atossa Therapeutics: Unlocking the Platform Potential of (Z)-Endoxifen Across Oncology & Rare Disease

Dr. Steven Quay explains how (Z)-endoxifen is being positioned as both an oncology backbone therapy and a potential treatment in rare diseases with substantial unmet need.

  FEATURED EDITORIAL

  COMPANY PROFILE

Lifecore is a U.S.-based Contract Development and Manufacturing Organization specializing in the development, fill/finish, and commercialization of sterile injectables. With a 40+ year regulatory track record and 20+ commercial products, Lifecore offers end-to-end services with experience spanning straightforward to complex formulations.  We support organizations of all sizes across pre-clinical, clinical, and commercial stages. Click here for more.

  WHITEPAPERS & WEBINARS

Drug Development & Delivery
WHITEPAPER - Stop Guessing. Start Predicting: Rethinking Early Oral Drug Development

WHITEPAPER - Stop Guessing. Start Predicting: Rethinking Early Oral Drug Development

Why Early Development Requires a Different Decision Model

Early oral drug development is an exercise in working under constraint. Teams are asked to make consequential decisions when materials are limited, timelines are tight, and the data are incomplete. Traditionally, formulation …

WHITEPAPER - Small Molecules: Choosing the Right Development Path

WHITEPAPER - Small Molecules: Choosing the Right Development Path

Summary

The white paper, Small Molecules: Choosing the Right Development Path, outlines a structured, risk-minimized approach to early CMC (Chemistry, Manufacturing, and Controls) development for small-molecule drugs—particularly for startups and virtual pharma companies with limited resources.

Key messages:

  • Start
…

WHITEPAPER - How Advanced Containment Technology Is Reshaping High-Potency API Micronization

WHITEPAPER - How Advanced Containment Technology Is Reshaping High-Potency API Micronization

       
By:
Harry Wade, Technical Associate, and Rosie Bird, EHS Lead, Catalent Dartford

The pharmaceutical industry faces a growing manufacturing challenge as therapeutic compounds become increasingly potent and targeted. Oncology and hormonal APIs, often designed for ultra-low dosing, promise meaningful clinical …

  DRUG DEVELOPMENT DIRECT RESOURCES

Upcoming eNewsletter Features:

April 15 – Prefilled Syringes
April 22 – Particle Design Technology